Denali Therapeutics' (DNLI) "Sell (D-)" Rating Reaffirmed at Weiss Ratings

Key Points

• Denali Therapeutics' stock has been given a "sell (D-)" rating by Weiss Ratings, amidst various analysts holding differing views on the stock's potential.
• Despite the negative rating from Weiss, the consensus among analysts remains a "Buy" with an average price target of $33.50, following updates from firms such as TD Cowen and Morgan Stanley.
• Denali Therapeutics' share price has shown fluctuations, recently trading at $15.65, with earnings per share reported at negative ($0.72) for the last quarter, beating analyst expectations by $0.02.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report)'s stock had its "sell (d-)" rating restated by equities research analysts at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

DNLI has been the subject of a number of other reports. TD Cowen upgraded Denali Therapeutics to a "strong-buy" rating in a research note on Monday, July 28th. Cantor Fitzgerald restated an "overweight" rating on shares of Denali Therapeutics in a research report on Monday, September 8th. Finally, Morgan Stanley cut their price objective on Denali Therapeutics from $33.00 to $30.00 and set an "overweight" rating on the stock in a report on Monday, August 18th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $33.50.

Denali Therapeutics Price Performance

Shares of NASDAQ DNLI traded up $0.75 during midday trading on Wednesday, reaching $15.65. 1,843,151 shares of the company traded hands, compared to its average volume of 2,107,827. The firm has a market cap of $2.29 billion, a PE ratio of -5.59 and a beta of 1.30. The stock's 50-day simple moving average is $14.52 and its 200-day simple moving average is $14.23. Denali Therapeutics has a 12 month low of $10.57 and a 12 month high of $33.33. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.27 and a current ratio of 10.27.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.74) by $0.02. During the same period in the prior year, the firm earned ($0.59) EPS. As a group, equities analysts anticipate that Denali Therapeutics will post -2.71 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Alexander O. Schuth sold 2,937 shares of the business's stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $13.58, for a total value of $39,884.46. Following the completion of the transaction, the insider owned 242,346 shares of the company's stock, valued at $3,291,058.68. The trade was a 1.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Carole Ho sold 2,937 shares of Denali Therapeutics stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $13.58, for a total value of $39,884.46. Following the completion of the transaction, the insider owned 217,391 shares in the company, valued at approximately $2,952,169.78. This represents a 1.33% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 6,680 shares of company stock worth $91,569. 12.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Denali Therapeutics

Institutional investors have recently modified their holdings of the company. Marex Group plc bought a new position in shares of Denali Therapeutics during the 2nd quarter worth $3,665,000. State of Wyoming bought a new stake in shares of Denali Therapeutics during the second quarter valued at approximately $29,000. Hudson Bay Capital Management LP raised its stake in shares of Denali Therapeutics by 16.0% in the second quarter. Hudson Bay Capital Management LP now owns 290,000 shares of the company's stock worth $4,057,000 after purchasing an additional 40,000 shares during the last quarter. Caxton Associates LLP purchased a new stake in Denali Therapeutics during the second quarter valued at $199,000. Finally, Headlands Technologies LLC bought a new stake in Denali Therapeutics during the second quarter valued at about $26,000. 92.92% of the stock is owned by institutional investors and hedge funds.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.